TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Less pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival signs of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of CHX ADS
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma levels of plasminogen activator-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerance of UK-279,276
Endpoint domain: Adverse events/effects
Primary endpoint: patient anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: patient satisfaction with the surgical and anesthetic experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: frequency of postoperative problems within 72 hours
Endpoint domain: Adverse events/effects
Primary endpoint: daily folic acid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smoking cessation at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain evaluated by self-assessment 100-mm VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Root Coverage (MRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Width of Keratinized Gingiva (KGW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trigger delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue penetration of tigecycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean lifetime cost of direct medical care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-peptide excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowered concentrations of glutamate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the curve of VAS (AUC(VAS))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in gray matter fraction (GMF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in white matter fraction (WMF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting FVIIa concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary excretion of CTX‐II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of vision‐impairing central‐involved diabetic macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT attenuation of coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CTDIvol and dose length product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved target range Hb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular diastolic dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reinfarction
Endpoint domain: Adverse events/effects
Primary endpoint: effectiveness of cognitive-behavioral intervention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CDRS-R scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum viral load levels less than 500 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median increase in CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease of depression levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrent atrial tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to complete the full NOTES procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: skin malondialdehyde concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: total amount of additional lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical symptom-sign score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma controlled test (ACT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for donor red blood cells
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical and biochemical blood tests within age norm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: status change from frail to non-frail
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: newly diagnosed as frail
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected reticulocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD4+ lymphocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of EUS-FNB vs. EUS-FNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for tumors other than PDAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events recorded after procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency/severity of hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharyngeal fat pad area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of spirometry tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal cancer risk reduction
Endpoint domain: Mortality/survival
Primary endpoint: serious and intermediate procedural-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Cmax of bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rise in heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-CZP antibody development
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet reactivity (PR) at hour 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Classification of albuminuria states
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to early identification of CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of positive surgical margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: sick leave due to lumbopelvic pain (LPP)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: ocular complications
Endpoint domain: Adverse events/effects
Primary endpoint: systemic complications
Endpoint domain: Adverse events/effects
Primary endpoint: EPDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in antisocial behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemical hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: severe hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in thoracalgia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in intensity of gastroesophageal reflux disease symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall MDRO prevalence density
Endpoint domain: Adverse events/effects
Primary endpoint: New methicillin-resistant Staphylococcus aureus acquisitions
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically defined catheter-associated urinary tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative ileus
Endpoint domain: Adverse events/effects
Primary endpoint: Acute voiding difficulty
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of drug combinations
Endpoint domain: Adverse events/effects
Primary endpoint: change in coronary heart disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in hemoglobin A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interference of pain with mood, sleep, and enjoyment of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of prescription items for formulary drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of items prescribed per prescribing unit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Estimated savings from formulary creation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to follow commands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in hemorheology parameters (HSR, LSR, HCT, profibrin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of the burden of opioid dependency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of violence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the proportion of adverse drug events (ADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in incontinence care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mobility care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residents' outcomes in mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of the global score of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ultrasonographic reflux time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Color difference (∆E)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse events related to medication
Endpoint domain: Adverse events/effects
Primary endpoint: Change in step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emergence of agitation or psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cognitive or functional decline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: hippocampal and whole-brain volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinical infections
Endpoint domain: Adverse events/effects
Primary endpoint: Serum anti-Müllerian hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: dGEMRIC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month best spectacle-corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of perforation or need for therapeutic penetrating keratoplasty
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in serum prohepcidin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in interleukin‐6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ultrasensitive C‐reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of peritoneal sclerosis (PS)
Endpoint domain: Mortality/survival
Primary endpoint: Mass transfer area coefficient (MTAC) of creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically driven events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient use of self-care materials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of CMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean hemoglobin change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving hemoglobin increase > or =1 g/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one year mortality
Endpoint domain: Mortality/survival
Primary endpoint: Increase in lumbar spine and hip BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in serum bone turnover markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDA coronary sinus concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-10 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular risk associated with alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Causal effect of smoking on schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of CPTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allodynia-like pain prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in VCAM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in ICAM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Expression of TGFbeta1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of type I to type III collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of TIMP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median number of unused pills
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean morphine equivalents prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Success rate of canalith repositioning procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28-ESR remission at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic disease progression (van der Heijde-modified total Sharp score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Disability Index reduction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nisonger Child Behavior Rating Form Disruptive-Total subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nisonger Child Behavior Rating Form Social Competence subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antisocial Behavior Scale Reactive Aggression subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sufficient serum 25‐hydroxy vitamin D (25‐OHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of TMC120 vaginal gel
Endpoint domain: Adverse events/effects
Primary endpoint: Stability after 6 months of follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived instability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proportion of culture-positive swabs
Endpoint domain: Adverse events/effects
Primary endpoint: mean number of species
Endpoint domain: Adverse events/effects
Primary endpoint: growth of CoNS
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of troponin I postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Airway resistance at 6 h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total coronary artery calcium score progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tensile strength (TD) after rehydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static modulus (SM) after heat treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-adjusted life years gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: C max levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100-day transplantation-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: 100-day cumulative mortality
Endpoint domain: Mortality/survival
Primary endpoint: 600-day IFD-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: plasma triglycerides concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apoA-II concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage gastric retention at 120 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: rate of gastric emptying in the first 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cervical flexor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of FIM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients hospitalized
Endpoint domain: Mortality/survival
Primary endpoint: anti-atherosclerotic endothelial expression quotient Q
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Component Summary Scores (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental Component Summary Scores (MCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: occurrences of ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: moderate and severe bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean AMP recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nauseogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bacterial colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Co-infections of bacteria or virus and bacteria
Endpoint domain: Adverse events/effects
Primary endpoint: resolution of symptoms at day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in externalising psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for face mask removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement during face mask removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived difficulty of face mask removal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical improvement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications of wound healing
Endpoint domain: Adverse events/effects
Primary endpoint: Need for intubation or tracheotomy
Endpoint domain: Adverse events/effects
Primary endpoint: KOOS Questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TUG Questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative number of aggressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of dental fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in low frequency oscillations of systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fast gait velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gain in height (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attempts to position hardware
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: failure/relapse rates
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of spirochetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes